Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Quarterly and Monthly TOUR006 in Participants With Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein

NCT06362759 is registered in ClinicalTrials.gov with Tourmaline Bio, Inc., a Novartis Company as lead sponsor.

NCT NCT06362759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06362759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Quarterly and Monthly TOUR006 in Participants With Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein
Lead sponsor
Tourmaline Bio, Inc., a Novartis Company
Phase
Phase 2
Overall status
Completed
Start date
May 15, 2024
Completion date
December 4, 2025
Enrollment
143 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

c-reactive protein, chronic kidney diseases, chronic kidney insufficiency, chronic renal diseases, chronic renal insufficiency, high sensitivity c-reactive protein, hs-crp, hscrp, kidney insufficiency, chronic